Results from the Phase 3 X-TOLE2 Study Evaluating Azetukalner, a Novel, Potent KV7 Channel Opener, in Adults With Focal Onset Seizures (FOS)
Results from the Phase 3 X-TOLE2 Study Evaluating Azetukalner, a Novel, Potent KV7 Channel Opener, in Adults With Focal Onset Seizures (FOS)
April 19, 2026
Congress: 2026 Annual Meeting of the American Academy of Neurology (AAN) (April 19, 2026)
Authors: French, JA et al.